Innoviva (INVA) Cash & Equivalents (2010 - 2026)

Innoviva (INVA) has 17 years of Cash & Equivalents data on file, last reported at $603.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 89.0% year-over-year to $603.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $603.1 million (up 89.0% YoY) and the FY2025 annual result came in at $550.9 million, up 80.66% from the prior year.
• Cash & Equivalents climbed to $603.1 million in Q1 2026, from $550.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $603.1 million in Q1 2026 to a low of $144.0 million in Q1 2023.
• A 5-year average of $299.5 million and a median of $283.6 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 555.45% — and 2023, when it slumped 40.16%.
• Tracing INVA's Cash & Equivalents over 5 years: stood at $291.0 million in 2022, then sank by 33.51% to $193.5 million in 2023, then soared by 57.59% to $305.0 million in 2024, then soared by 80.66% to $550.9 million in 2025, then gained by 9.46% to $603.1 million in 2026.
• The last three Cash & Equivalents figures came in at $603.1 million (Q1 2026), $550.9 million (Q4 2025), and $476.5 million (Q3 2025), per Business Quant data.